Processing...
Clinical Trials for Colon Cancer
Search
Search
There are 224 active trials for advanced/metastatic colon cancer.
Click on a trial to see more information.
224 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with untreated advanced/metastatic colorectal adenocarcinoma (ECOG 0–1), measurable disease, and adequate organ function receive ProAgio—an investigational pegylated peptide that targets integrin αvβ3 on cancer-associated fibroblasts and endothelial cells to induce apoptosis and remodel stroma—combined with FOLFIRI (irinotecan/infusional 5-FU) plus bevacizumab. Prior FOLFOX for adjuvant disease >1 year is allowed in expansion, while prior FOLFIRI or 5-FU–based therapy for metastatic disease is excluded.
ClinicalTrials.gov ID: NCT06867822
TrialFetch AI summary: Adults with relapsed/refractory gastrointestinal cancers (gastric adenocarcinoma [CDH17+], colorectal adenocarcinoma, or well-differentiated mid/hindgut NETs) receive lymphodepleting fludarabine/cyclophosphamide followed by a single infusion of CHM-2101, an autologous third-generation CAR T therapy targeting cadherin-17. Single-arm dose escalation/expansion; bridging chemo allowed between leukapheresis and lymphodepletion.
ClinicalTrials.gov ID: NCT06055439
TrialFetch AI summary: Adults with advanced/metastatic solid tumors lacking effective standard options (broad basket with prioritized cohorts such as CRC, SCLC, HNSCC, NSCLC, pancreatic, and bladder; some genomically enriched) receive oral single‑agent CP-383 in dose escalation and tumor‑specific expansions. CP-383 is a first‑in‑class small molecule designed to modulate lipid‑binding pockets on oncogenic proteins (exact target undisclosed).
ClinicalTrials.gov ID: NCT07030257
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Adults with advanced/metastatic FAP-expressing solid tumors (including pancreatic, multiple breast cancer subtypes, platinum-resistant/refractory ovarian, and other FAP-positive GI tumors) and ECOG 0–1 receive intravenous LY4337713, a lutetium-177–labeled small-molecule radioligand targeting fibroblast activation protein on cancer-associated fibroblasts to deliver beta radiation to the tumor microenvironment, on Q4–6 week cycles. Expansion cohorts are tumor-specific after dose escalation/optimization.
ClinicalTrials.gov ID: NCT07213791
TrialFetch AI summary: Adults with advanced, refractory solid tumors (ECOG 0–1) receive an allogeneic, off‑the‑shelf iPSC‑derived CAR T product (FT836) targeting stress‑inducible MICA/MICB (engineered to reduce antigen shedding) as monotherapy or combined with trastuzumab (HER2), cetuximab (EGFR), and/or paclitaxel. Multi‑arm cohorts assess safety and preliminary activity to establish RP2D for the combination regimens.
ClinicalTrials.gov ID: NCT07216105
TrialFetch AI summary: Monotherapy ALE.P03, a Claudin‑1–targeted antibody–drug conjugate that delivers a topoisomerase I inhibitor payload, for adults with centrally confirmed CLDN1-positive advanced/metastatic solid tumors limited to mCRC, intrahepatic cholangiocarcinoma, squamous NSCLC, urothelial carcinoma, or cervical squamous cell carcinoma. Requires RECIST-measurable, ECOG 0–1 disease with prior standard therapy (dose escalation: refractory/intolerant to all; expansion/phase II: 1–2 prior lines and prior targeted therapy if actionable drivers), excluding active CNS metastases and significant ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07169734
TrialFetch AI summary: Adults with advanced/metastatic colorectal adenocarcinoma, NSCLC, or pancreatic ductal adenocarcinoma after at least one prior systemic therapy receive IV PHN-012, a first-in-human investigational antibody–drug conjugate (target undisclosed; exclusion suggests possible topoisomerase‑I payload). Open-label dose escalation with tumor-specific expansion; requires measurable disease, ECOG 0–1, adequate organs, and available tissue; excludes prior topo‑I ADCs, unstable CNS mets, and active/past ILD/pneumonitis.
ClinicalTrials.gov ID: NCT07127874
TrialFetch AI summary: Adults with ECOG 0–1 advanced/metastatic CA19-9–expressing solid tumors (including PDAC, cholangiocarcinoma, urothelial, colorectal, gastroesophageal junction, endometrial, and epithelial ovarian cancers) that have progressed after standard therapies; includes a randomized dose-optimization component specifically for second-line or later PDAC with no remaining expected-benefit options. Treatment is IV BNT329, a CA19-9 (sialyl-Lewis A)–targeting antibody–drug conjugate delivering a topoisomerase I inhibitor payload, given q3w or (if opened) q2w, with an optional CA19-9 antibody pre-dosing strategy in one cohort.
ClinicalTrials.gov ID: NCT07186842
TrialFetch AI summary: Adults with measurable advanced/metastatic breast cancer (progressed after ≥1 line endocrine therapy and a CDK4/6 inhibitor) or advanced/metastatic colorectal cancer (previously treated per standard options, plus one cohort without prior chemo for metastatic disease), ECOG 0–1. Participants receive oral investigational agent PF-08032562 (target/mechanism not publicly described) as monotherapy or combined with fulvestrant (breast) or cetuximab or FOLFOX + bevacizumab (colorectal) in 28-day cycles with dose escalation/expansion.
ClinicalTrials.gov ID: NCT07318805